Predicting Drug-Target Interactions Via Dual-Stream Graph Neural Network

Drug target interaction prediction is a crucial stage in drug discovery. However, brute-force search over a compound database is financially infeasible. We have witnessed the increasing measured drug-target interactions records in recent years, and the rich drug/protein-related information allows th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:IEEE/ACM transactions on computational biology and bioinformatics Ročník 21; číslo 4; s. 948 - 958
Hlavní autoři: Li, Yuhui, Liang, Wei, Peng, Li, Zhang, Dafang, Yang, Cheng, Li, Kuan-Ching
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States IEEE 01.07.2024
Témata:
ISSN:1545-5963, 1557-9964, 1557-9964
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Drug target interaction prediction is a crucial stage in drug discovery. However, brute-force search over a compound database is financially infeasible. We have witnessed the increasing measured drug-target interactions records in recent years, and the rich drug/protein-related information allows the usage of graph machine learning. Despite the advances in deep learning-enabled drug-target interaction, there are still open challenges: (1) rich and complex relationship between drugs and proteins can be explored; (2) the intermediate node is not calibrated in the heterogeneous graph. To tackle with above issues, this paper proposed a framework named DSG-DTI. Specifically, DSG-DTI has the heterogeneous graph autoencoder and heterogeneous attention network-based Matrix Completion. Our framework ensures that the known types of nodes (e.g., drug, target, side effects, diseases) are precisely embedded into high-dimensional space with our pretraining skills. Also, the attention-based heterogeneous graph-based matrix completion achieves highly competitive results via effective long-range dependencies extraction. We verify our model on two public benchmarks. The result of two publicly available benchmark application programs show that the proposed scheme effectively predicts drug-target interactions and can generalize to newly registered drugs and targets with slight performance degradation, outperforming the best accuracy compared with other baselines.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1545-5963
1557-9964
1557-9964
DOI:10.1109/TCBB.2022.3204188